Buzz Stocks: Wells Fargo & Co, Herbalife Ltd., and ZIOPHARM Oncology Inc.

• WFC is down 2.3% at $47.85, as traders pan its latest earnings report. Wells Fargo & Co is 12% lower year-to-date, with recent rebound attempts running into resistance around the $51 level. Call buyers were growing hot on the stock ahead of earnings, with WFC's 10-day call/put volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) of 2.43 sitting higher than 98% of all other readings from the past year. Likewise, 14 analysts currently rate WFC a "buy" or better. An exodus of option bulls or a round of downgrades could exacerbate post-earnings losses for the stock.

• HLF is up 18.8% at $70.50 -- and earlier notched a new two-year high of $72.22 -- after the Federal Trade Commission (FTC) declared the company is not a pyramid scheme. HLF will settle with the FTC to the tune of $200 million, and agreed to restructure its U.S. business operations. The surge is much to the dismay of activist investor Bill Ackman, who has been publicly chastising the nutrition stock for years. Meanwhile, the HLF board is now allowing fellow activist Carl Icahn -- who acknowledged that he and Ackman "are on friendly terms [but] agreed to disagree (vehemently)" on HLF --  to up his stake from 25% to 34.99%. "I believe that now the cloud over Herbalife is gone, the Company will continue to grow," Icahn wrote in a statement. HLF is up 32.4% year-to-date, rising over 66% since hitting an annual low in February. There's likely some option players kicking rocks after this news, with HLF's 10-day ISE/CBOE/PHLX put/call volume ratio of 3.26 sitting in the 90th percentile of its annual range.

• ZIOP is down 12.7% at $4.97, after a patient being treated with an experimental gene therapy drug for an aggressive type of brain cancer died just days after treatment. ZIOPHARM Oncology Inc. called it an "isolated case," and said "we believe that preliminary overall survival remains encouraging." ZIOP shares are down 41.8% so far this year, with rally attempts contained by their 160-day moving average , and the stock is now dangerously close to a new annual low. There's more than a few call players nervous after this news, with ZIOP's 50-day ISE/CBOE/PHLX call/put volume ratio of a staggering 30.81 sitting higher than 98% of all other readings from the past year. 

Schaeffer's Weekly Volatility Trader subscribers just made 230% GAINS on a Cree, Inc. straddle! Sign up now for a discounted 30-day trial.